Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer.

Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer.

BACKGROUND: Selective cyclooxygenase inhibitors may retard the progression of cancer, but they have enhanced thrombotic potential. We report on cardiovascular adverse events in patients receiving rofecoxib to reduce rates of recurrence of colorectal cancer. METHODS: All serious adverse events that...

Szczegółowa specyfikacja

Opis bibliograficzny
Główni autorzy:	Kerr, D, Dunn, J, Langman, M, Smith, J, Midgley, R, Stanley, A, Stokes, J, Julier, P, Iveson, C, Duvvuri, R, McConkey, C
Format:	Journal article
Język:	English
Wydane:	2007

Podobne zapisy

Phase III randomized trial assessing rofecoxib in the adjuvant setting of colorectal cancer: final results of the VICTOR trial.
od: Midgley, R, i wsp.
Wydane: (2010)

VICTOR: A phase III placebo-controlled trial of rofecoxib in colorectal cancer patients following surgical resection
od: Kerr, D, i wsp.
Wydane: (2008)

VICTOR: A PHASE III PLACEBO-CONTROLLED TRIAL OF ROFECOXIB IN COLORECTAL CANCER PATIENTS FOLLOWING SURGICAL RESECTION
od: Midgley, R, i wsp.
Wydane: (2008)

Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study.
od: Gray, R, i wsp.
Wydane: (2007)

Adjuvant therapy of colorectal cancer.
od: Midgley, R, i wsp.
Wydane: (2000)

ABC of colorectal cancer: adjuvant therapy.
od: Midgley, R, i wsp.
Wydane: (2000)

QUASAR: A randomized study of adjuvant chemotherapy (CT) vs observation including 3238 colorectal cancer patients.
od: Gray, R, i wsp.
Wydane: (2004)

Immunotherapy for colorectal cancer: potential application in an adjuvant setting.
od: Kerr, D, i wsp.
Wydane: (2000)

Immunotherapy for colorectal cancer: Potential application in an adjuvant setting
od: Kerr, D, i wsp.
Wydane: (2000)

Adjuvant chemotherapy for stage II colorectal cancer: the time is right!
od: Midgley, R, i wsp.
Wydane: (2005)

QUASAR Collaborative Group: a randomised study of adjuvant chemotherapy (CT) vs observation in predominantly stage II colorectal cancer
od: Kerr, D, i wsp.
Wydane: (2004)

Rofecoxib Induced Purpura
od: Dogra Sunil, i wsp.
Wydane: (2004-01-01)

Adjuvant chemotherapy for stage II colorectal cancer: who should receive therapy and with what?
od: Midgley, R, i wsp.
Wydane: (2005)

The NSAID roller coaster: more about rofecoxib.
od: Aronson, J
Wydane: (2006)

CAPECITABINE (CAPE) +/- BEVACIZUMAB (BEV) IN THE ADJUVANT TREATMENT OF COLORECTAL CANCER (CRC) FIRST AND FINAL TOXICITY RESULTS FROM THE INTERNATIONAL PHASE III QUASAR2 TRIAL
od: Midgley, R, i wsp.
Wydane: (2012)

Rofecoxib, Diclofenac e Indometacina aumentam o risco de doença cardiovascular
od: Filipa Almada Lobo
Wydane: (2006-11-01)

Simultaneous Determination of Rofecoxib and Tizanidine by HPTLC
od: Uttam D. Pawar, i wsp.
Wydane: (2009-01-01)

Rofecoxib for dysmenorrhoea: meta-analysis using individual patient data
od: McQuay Henry J, i wsp.
Wydane: (2004-07-01)

Rofecoxib-Induced Hepatotoxicity: A Forgotten Complication of the Coxibs
od: Brian Yan, i wsp.
Wydane: (2006-01-01)

Individual patient meta-analysis of single-dose rofecoxib in postoperative pain
od: Edwards, J, i wsp.
Wydane: (2004)

Individual patient meta-analysis of single-dose rofecoxib in postoperative pain
od: McQuay Henry J, i wsp.
Wydane: (2004-02-01)

Synergistic effect of gefitinib and rofecoxib in mesothelioma cells
od: Sacchi Ada, i wsp.
Wydane: (2010-02-01)

Adjuvant chemotherapy for colorectal cancer.
od: Kerr, D, i wsp.
Wydane: (1996)

Rofecoxib improves quality of life in patients with hip or knee osteoarthritis
od: R Theiler, i wsp.
Wydane: (2002-10-01)

Single dose oral rofecoxib for acute postoperative pain in adults.
od: Bulley, S, i wsp.
Wydane: (2009)

Single dose oral rofecoxib for acute postoperative pain in adults.
od: Bulley, S, i wsp.
Wydane: (2009)

Single-dose rofecoxib for acute postoperative pain in adults: a quantitative systematic review
od: Barden, J, i wsp.
Wydane: (2002)

The effect of rofecoxib and diclofenac on blood picture in male patients
od: Mohammed Z.K. Al-Hayali
Wydane: (2008-12-01)

Analysis of adverse events and quality of life data for an economic evaluation of adjuvant chemotherapy in colorectal cancer: when can we stop collecting?
od: Boyd Kathleen A, i wsp.
Wydane: (2011-12-01)

Single-dose rofecoxib for acute postoperative pain in adults: a quantitative systematic review
od: McQuay Henry J, i wsp.
Wydane: (2002-06-01)

Immunotherapy for colorectal cancer.
od: Midgley, R, i wsp.
Wydane: (2003)

Identification of New Rofecoxib-Based Cyclooxygenase-2 Inhibitors: A Bioinformatics Approach
od: Rozires P. Leão, i wsp.
Wydane: (2020-08-01)

Rofecoxib for dysmenorrhoea: meta-analysis using individual patient data
Wydane: (2004)

Colorectal cancer.
od: Nicum, S, i wsp.
Wydane: (2003)

Colorectal cancer
od: Nicum, S, i wsp.
Wydane: (2003)

Adjuvant chemotherapy for stage II colon cancer: less complicated than we thought.
od: Midgley, R, i wsp.
Wydane: (2013)

Anti-inflammatory treatment with acetylsalicylate or rofecoxib is not neuroprotective in Huntington's disease transgenic mice
od: Fran Norflus, i wsp.
Wydane: (2004-11-01)

Chemotherapy for colorectal cancer.
od: Nicum, S, i wsp.
Wydane: (2000)

Hidden Cardiotoxicity of Rofecoxib Can be Revealed in Experimental Models of Ischemia/Reperfusion
od: Gábor B. Brenner, i wsp.
Wydane: (2020-02-01)

SKIN PERMEATION ENHANCEMENT EFFECTS OF ASCORBIC ACID AND TRIETHYL CITRATE ON ROFECOXIB
od: MALAY K. DAS, i wsp.
Wydane: (2008-01-01)